FDA's Biosimilarity Guidance Holds Uncertain Implications
On Jan. 20, the public comment period for the U.S. Food and Drug Administration's draft guidance on demonstrating biosimilarity closed.[1] This document, issued Oct. 29, 2025, proposes "major updates to simplify...To view the full article, register now.
Already a subscriber? Click here to view full article